Voluntary announcement pivotal registrational Phase IIb study of LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) monotherapy in advanced EP-NEC selected as LBA and three studies selected for Proffered Paper presentations at 2026 ESMO
Filed with HKEX · Stock code 9887 · · 4 pages · English
Nanjing Leads Biolabs Co., Ltd. 南京维立志博生物科技股份有限公司 (A joint stock company established in the People's Republic of China with limited liability) (Stock Code: 9887) VOLUNTARY ANNOUNCEMENT PIVOTAL REGISTRATIONAL PHASE IIB STUDY OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) MONOTHERAPY IN ADVANCED EP-NEC SELECTED AS LBA AND THREE STUDIES SELECTED FOR PROFFERED PAPER PRESENTATIONS AT 2026 ES
Nanjing Leads Biolabs Co., Ltd. on 6ix
Earlier from Nanjing Leads Biolabs
- WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC
- Voluntary announcement updated data from phase ii clinical study of lbl-024 (opamtistomig, pd-L1/4-1BB bispecific antibody) in combination with chemotherapy as first-line treatment for nsclc presented orally at wclc 2026
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage
- Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
- Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement
Later from Nanjing Leads Biolabs
- Leads Biolabs’ Pivotal Phase IIb Study of Opamtistomig (LBL-024) in Advanced EP-NEC Selected as ESMO 2026 Late-Breaking Abstract; Three Studies Selected for Proffered Paper Presentations
- 2026 Interim report
- Voluntary announcement LBL-024 (opamtistomig, PD-L1/4-1BB bispecific antibody) granted Orphan Drug Designation in Japan
- Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Nanjing Leads Biolabs into a list and get an email when it puts out news.
Follow Nanjing Leads Biolabs